BiotechCSLThree reporting season scenarios to consider for CSL: Morgan StanleyKerry Sun·1 February 2023
BiotechALABiotech Arovella to receive Europe patent for its iNKT cell therapy platformMarket Index·7 November 2022
BiotechMesoblast’s trials to reduce adverse cardiovascular events get hearty response, shares up 7% heading into the closeMarket Index·19 July 2022
BiotechNTINeurotech study finds children with autism benefit from cannabis product Jonathon Davidson·8 July 2022
BiotechEIQEcho IQ to present AI heart disease detection tech at high-impact Barcelona conference Jonathon Davidson·7 July 2022
BiotechDXBDimerix to launch diabetes-related disease trial in Australia; FDA interest persists Jonathon Davidson·7 June 2022
BiotechIHLLatest trial results suggest Incannex's IHL-42X treatment makes for 'higher' quality sleepJonathon Davidson·3 June 2022
BiotechATHAlterity launches phase 2 trial for rare brain-related disordersJonathon Davidson·2 June 2022
BiotechCYPCynata Therapeutics jumps as FDA OK’s stem cell rejection treatment Jonathon Davidson·26 May 2022
BiotechPAAPharmAust looks to Eastern Europe for unvaccinated COVID trial participants Jonathon Davidson·24 May 2022
BiotechACWActinogen reassesses its priorities: Clinical programs refocus on cognition Company Insights·4 May 2022
BiotechKZAKazia finalises second phase of novel brain cancer treatment Jonathon Davidson·22 April 2022
Market WrapsTLGCYLEvening Wrap: ASX 200 jumps 120 points as gold stocks surge, new FY flows lift miners and healthcare
Technical AnalysisALLARBChartWatch ASX Scans: Aristocrat Leisure, Droneshield, Fortescue, Harvey Norman, Nextdc, Origin Energy, Webjet
Market WrapsMorning Wrap: ASX 200 to rise, Dow soars to all-time highs, Nasdaq tanks as chip stocks tumble